At page 70, line 17, insert --(SEQ ID NO:56)-- after "TAG-3')"

At page 72, line 7, insert --(SEQ ID NO:57)-- after "AAC-3')"

At page 72, line 8, insert --(SEQ ID NO:58)-- after "TTC-3' "

At page 73, line 7, insert --(SEQ ID NO:59)-- after "TGC-3')"

At page 73, line 14, insert --(SEQ ID NO:60)-- after "GC3' "

At page 75, line 11, insert --(SEQ ID NO:61)-- after "TAG-3' "

At page 75, line 13, insert --(SEQ ID NO:62)-- after "GGA-3' "

At page 76, line 16, insert --(SEQ ID NO:63)-- after "GAC-3')"

At page 76, line 33, insert --(SEQ ID NO:64)-- after "ACC-3')"

IN THE CLAIMS

Cancel claims 24, 27-39, 77, 79, 81, 86, 87-94, 97-101 and 104-106 without prejudice or disclaimer.

In line 1 of each of claims 70-76, 84, 85, 96, 102, and 107-109, delete "Method" and insert insert - - A method - -.

Amend the claims as follows, without prejudice or disclaimer:

69. (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

R^2 GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC
CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC
AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG
GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC
TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC
CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG
GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT
TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC
CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG

GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT
TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT
AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC
CTA CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or is a DNA comprising a sequence coding for a polypeptide which can be cleaved *in vivo*; and

B) DNA comprising the sequence:

R^2 GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC
CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC
CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA
GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA
AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC
ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG
AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC
CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC
AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA
CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT
AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG
TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT
GAG GAC TCA GGC ACC ACA,

or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or represents DNA coding for a polypeptide which can be cleaved *in vivo*;

C) a DNA sequence of A or B encoding at least one conservative amino acid substitution;

D) a DNA sequence of A or B encoding at least one amino acid substitution at a glycosylation site;

E) a DNA sequence of A or B encoding at least one amino acid substitution at a proteolytic cleavage site; and

F) a DNA sequence of A or B encoding at least one amino acid substitution at a cysteine residue.

78. (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

```
CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT
AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA
ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG
GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC
ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC
TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG
ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT
GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC
CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA
CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT
CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT
AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC
CAG ATT GAG AAT
```

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

```
CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT
AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA
ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG
GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC
ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC
TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG
ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT
GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC
CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA
CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT
CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT
AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC
CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC
ACC ACA
```

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

T0930

```
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT
CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA
GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG
CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC
TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG
AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC
TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC
TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT
```

, or a C- and/or N- terminally shortened sequence thereof; and

D) DNA comprising the sequence:

T0931

```
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT
CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA
GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG
CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC
TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG
AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC
TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC
TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA
GGC ACC ACA
```

, or a C- and/or N- terminally shortened sequence thereof;

E) a DNA sequence of A, B, C or D encoding at least one conservative amino acid substitution;

F) a DNA sequence of A, B, C or D encoding at least one amino acid substitution at a glycosylation site;

G) a DNA sequence of A, B, C or D encoding at least one amino acid substitution at a proteolytic cleavage site; and

H) a DNA sequence of A, B, C or D encoding at least one amino acid substitution at a cysteine residue.

~~80.~~ 10. (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

```
ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT
CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA
GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG
CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC
TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG
AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC
TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC
TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT
```

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

```
ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT
CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA
GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG
CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC
TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG
AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC
TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
```

TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC
TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA
GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

ATG GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC
CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC
AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG
GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC
TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC
CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG
GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT
TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC
CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG
GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT
TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT
AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC
CTA CCC CAG ATT GAG AAT

T0950
Fit
con

, or a C- and/or N- terminally shortened sequence thereof;

D) DNA comprising the sequence:

ATG GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC
CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC
AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG
GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC
TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC
CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG
GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT
TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC
CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG
GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT
TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT
AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC
CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC
TCA GGC ACC ACA

T0951

, or a C- and/or N- terminally shortened sequence thereof;

E) DNA comprising the sequence:

95

F

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA
CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC
TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC
AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA
TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC
AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT
CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC
AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA
ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC
CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC
CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC
AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC
TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC
TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG
AAG TTG TGC CTA CCC CAG ATT GAG AAT

T0960

, or a C- and/or N- terminally shortened sequence thereof;

F) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA
CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC
TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC
AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA
TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC
AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT
CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC
AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA
ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC
CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC
CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC
AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC
TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC
TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG
AAG TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC
ACT GAG GAC TCA GGC ACC ACA

T0961

, or a C- and/or N- terminally shortened sequence thereof;

G) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA

T0962

CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC
TCA GGG GTT ATT GGA GAT AGT GTG TGT CCC CAA GGA
AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT
ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC
TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG
TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG
GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG
GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG
TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC
TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC
CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC
TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC
ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

H) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA
CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC
TCA GGG GTT ATT GGA GAT AGT GTG TGT CCC CAA GGA
AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT
ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC
TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG
TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG
GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG
GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG
TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC
TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC
CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC
TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC
ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG
GGC ACT GAG GAC TCA GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof; and

I) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA
CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC
TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC
AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA
TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC

AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT
CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC
AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA
ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC
CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC
CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC
AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC
TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC
TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG
AAG TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC
ACT GAG GAC TCA GGC ACC ACA GTG CTG TTG CCC CTG
GTC ATT TTC TTT GGT CTT TGC CTT TTA TCC CTC CTC
TTC ATT GGT TTA ATG TAT CGC TAC CAA CGG TGG AAG
TCC AAG CTC TAC TCC ATT GTT TGT GGG AAA TCG ACA
CCT GAA AAA GAG GGG GAG CTT GAA GGA ACT ACT ACT
AAG CCC CTG GCC CCA AAC CCA AGC TTC AGT CCC ACT
CCA GGC TTC ACC CCC ACC CTG GGC TTC AGT CCC GTG
CCC AGT TCC ACC TTC ACC TCC AGC TCC ACC TAT ACC
CCC GGT GAC TGT CCC AAC TTT GCG GCT CCC CGC AGA
GAG GTG GCA CCA CCC TAT CAG GGG GCT GAC CCC ATC
CTT GCG ACA GCC CTC GCC TCC GAC CCC ATC CCC AAC
CCC CTT CAG AAG TGG GAG GAC AGC GCC CAC AAG CCA
CAG AGC CTA GAC ACT GAT GAC CCC GCG ACG CTG TAC
GCC GTG GTG GAG AAC GTG CCC CCG TTG CGC TGG AAG
GAA TTC GTG CGG CGC CTA GGG CTG AGC GAC CAC GAG
ATC GAT CGG CTG GAG CTG CAG AAC GGG CGC TGC CTG
CGC GAG GCG CAA TAC AGC ATG CTG GCG ACC TGG AGG
CGG CGC ACG CCG CGG CGC GAG GCC ACG CTG GAG CTG
CTG GGA CGC GTG CTC CGC GAC ATG GAC CTG CTG GGC
TGC CTG GAG GAC ATC GAG GAG GCG CTT TGC GGC CCC
GCC GCC CTC CCG CCC GCG CCC AGT CTT CTC AGA

, or a C- and/or N- terminally shortened sequence thereof;

J) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one conservative amino acid substitution;

K) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one amino acid substitution at a glycosylation site;

L) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one amino acid substitution at a proteolytic cleavage site; and

M) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one amino acid substitution at a cysteine residue.

82. (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 69 under conditions of moderate stringency.

83. (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

T0990

R^2	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val
	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
	cys	leu	pro	gln	ile	glu	asn							

, or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or is a polypeptide which can be cleaved *in vivo*; [and]

B) a polypeptide comprising the amino acid sequence:

T0991

R^2	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu

99

asn leu phe gln cys phe asn cys ser leu cys leu asn gly
thr val his leu ser cys gln glu lys gln asn thr val cys
thr cys his ala gly phe phe leu arg glu asn glu cys val
ser cys ser asn cys lys lys ser leu glu cys thr lys leu
cys leu pro gln ile glu asn val lys gly thr glu asp ser
gly thr thr

, or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or is a polypeptide which can be cleaved *in vivo*;

C) a polypeptide comprising the amino acid sequence of A or B with at least one conservative amino acid substitution;

D) a polypeptide comprising the amino acid sequence of A or B with at least one amino acid substitution at a glycosylation site;

E) a polypeptide comprising the amino acid sequence of A or B with at least one amino acid substitution at a proteolytic cleavage site; and

F) a polypeptide comprising the amino acid sequence of A or B with at least one amino acid substitution at a cysteine residue.

~~95.~~ (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim ~~83~~ under conditions of moderate stringency.

~~96.~~ (Amended) A polypeptide according to claim ~~83~~, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

asp ser val cys pro gln gly lys tyr ile his pro gln asn
asn ser ile cys cys thr lys cys his lys gly thr tyr leu

tyr asn asp cys pro gly pro gly gln asp thr asp cys arg
glu cys glu ser gly ser phe thr ala ser glu asn his leu
arg his cys leu ser cys ser lys cys arg lys glu met gly
gln val glu ile ser ser cys thr val asp arg asp thr val
cys gly cys arg lys asn gln tyr arg his tyr trp ser glu
asn leu phe gln cys phe asn cys ser leu cys leu asn gly
thr val his leu ser cys gln glu lys gln asn thr val cys
thr cys his ala gly phe phe leu arg glu asn glu cys val
ser cys ser asn cys lys lys ser leu glu cys thr lys leu
cys leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

T1010

leu val pro his leu gly asp arg glu lys arg asp ser val
cys pro gln gly lys tyr ile his pro gln asn asn ser ile
cys cys thr lys cys his lys gly thr tyr leu tyr asn asp
cys pro gly pro gly gln asp thr asp cys arg glu cys glu
ser gly ser phe thr ala ser glu asn his leu arg his cys
leu ser cys ser lys cys arg lys glu met gly gln val glu
ile ser ser cys thr val asp arg asp thr val cys gly cys
arg lys asn gln tyr arg his tyr trp ser glu asn leu phe
gln cys phe asn cys ser leu cys leu asn gly thr val his
leu ser cys gln glu lys gln asn thr val cys thr cys his
ala gly phe phe leu arg glu asn glu cys val ser cys ser
asn cys lys lys ser leu glu cys thr lys leu cys leu pro
gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

T1011

asp ser val cys pro gln gly lys tyr ile his pro gln asn
asn ser ile cys cys thr lys cys his lys gly thr tyr leu
tyr asn asp cys pro gly pro gly gln asp thr asp cys arg
glu cys glu ser gly ser phe thr ala ser glu asn his leu
arg his cys leu ser cys ser lys cys arg lys glu met gly
gln val glu ile ser ser cys thr val asp arg asp thr val
cys gly cys arg lys asn gln tyr arg his tyr trp ser glu
asn leu phe gln cys phe asn cys ser leu cys leu asn gly
thr val his leu ser cys gln glu lys gln asn thr val cys
thr cys his ala gly phe phe leu arg glu asn glu cys val
ser cys ser asn cys lys lys ser leu glu cys thr lys leu
cys leu pro gln ile glu asn val lys gly thr glu asp ser
gly thr thr

, or a C- and/or N- terminally shortened sequence thereof; and

D) a polypeptide comprising the amino acid sequence:

leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser	val
cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser	ile
cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn	asp
cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys	glu
ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his	cys
leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val	glu
ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly	cys
arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu	phe
gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val	his
leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys	his
ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys	ser
asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu	pro
gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr	thr

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one conservative amino acid substitution;

F) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one amino acid substitution at a glycosylation site;

G) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one amino acid substitution at a proteolytic cleavage site; and

H) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one amino acid substitution at a cysteine residue.

23

103. (Amended) A recombinant polypeptide which is nonglycosylated [or has a glycosylation pattern different from urinary-derived TNF inhibitor] or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of: :

A) a polypeptide comprising the amino acid sequence:

T1030

met asp ser val cys pro gln gly lys tyr ile his pro gln
asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his
leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn
gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn,

or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

T1031

met leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

T1032

met asp ser val cys pro gln gly lys tyr ile his pro gln
asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his
leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn

gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn val lys gly thr glu asp
ser gly thr thr

, or a C- and/or N- terminally shortened sequence thereof;

D) a polypeptide comprising the amino acid sequence:

T1040

met leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn val lys gly thr glu asp ser gly thr
thr

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence:

T1041

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

F) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn val lys gly thr glu asp ser gly thr
thr

, or a C- and/or N- terminally shortened sequence thereof;

G) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly asp ser val cys pro gln gly lys tyr ile his pro gln
asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his
leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn
gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

H) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly asp ser val cys pro gln gly lys tyr ile his pro gln

asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his
leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn
gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn val lys gly thr glu asp
ser gly thr thr

, or a C- and/or N- terminally shortened sequence thereof; [and]

I) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn val lys gly thr glu asp ser gly thr
thr val leu leu pro leu val ile phe phe gly leu cys leu
leu ser leu leu phe ile gly leu met tyr arg tyr gln arg
trp lys ser lys leu tyr ser ile val cys gly lys ser thr
pro glu lys glu gly glu leu glu gly thr thr thr lys pro
leu ala pro asn pro ser phe ser pro thr pro gly phe thr
pro thr leu gly phe ser pro val pro ser ser thr phe thr
ser ser ser thr tyr thr pro gly asp cys pro asn phe ala
ala pro arg arg glu val ala pro pro tyr gln gly ala asp
pro ile leu ala thr ala leu ala ser asp pro ile pro asn
pro leu gln lys trp glu asp ser ala his lys pro gln ser
leu asp thr asp asp pro ala thr leu tyr ala val val glu
asn val pro pro leu arg trp lys glu phe val arg arg leu
gly leu ser asp his glu ile asp arg leu glu leu gln asn
gly arg cys leu arg glu ala gln tyr ser met leu ala thr

trp	arg	arg	arg	thr	pro	arg	arg	glu	ala	thr	leu	glu	leu
leu	gly	arg	val	leu	arg	asp	met	asp	leu	leu	gly	cys	leu
glu	asp	ile	giu	glu	ala	leu	cys	gly	pro	ala	ala	leu	pro
pro	ala	pro	ser	leu	leu	arg							

, or a C- and/or N- terminally shortened sequence thereof;

J) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one conservative amino acid substitution;

K) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one amino acid substitution at a glycosylation site;

L) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one amino acid substitution at a proteolytic cleavage site; and

M) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one amino acid substitution at a cysteine residue.

Please insert new claims 107-115.

--107. A polypeptide according to claim ~~103~~, wherein said polypeptide is chemically derivatized.

~~108~~. A polypeptide having the ability to bind to TNF comprising an amino acid sequence as set forth in one of claims ~~69~~, ~~78~~, ~~80~~, ~~83~~, ~~96~~ and ~~103~~ with at least one intrasequence conservative amino acid substitution.

~~109~~. (Amended) A polypeptide according to claim ~~108~~, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

~~110~~. (Amended) A polypeptide according to claim ~~109~~, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

~~111~~. (Amended) A polypeptide according to claim ~~108~~, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

107

29 26

112. (Amended) A polypeptide according to claim 111, wherein said polypeptide includes a methionine at the amino-terminus.

30 26

113. (Amended) A polypeptide according to claim 109, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

F8 cont

31 25

114. (Amended) A polypeptide according to claim 108, wherein said polypeptide includes a methionine at the amino-terminus and said amino acid substitution is at a glycosylation site.

32 25

115. (Amended) A polypeptide according to claim 108, wherein said amino acid substitution is at a glycosylation site.--